Clinical studies have also revealed that gene-silencing therapies, such as the use of small interfering RNA and antisense oligonucleotides that target the TTR gene, dramatically reduced disease-causing TTR expression by the liver and significantly improved symptoms of patients with ATTRv amyloidosis [20, 21]. Here, TTR is linked to familial amyloid neuropathy.